Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Immune Checkpoint Inhibitors Market Size, Share, Trends, and Global Forecast to 2030 | Next-Generation Targets and Combination Therapies Create New Growth Opportunities

globenewswire.com
BMY Bristol-Myers Squibb is mentioned as a developer of immune checkpoint inhibitors, including Yervoy (ipilimumab), the first FDA-approved drug in this class. The company is also developing next-generation therapies, indicating a strong position in a growing market. GSK GlaxoSmithKline is listed as an active company in the immune checkpoint inhibitors market and is developing next-generation therapies, suggesting positive future prospects in this expanding therapeutic area. INCY Incyte is identified as a company active in the immune checkpoint inhibitors market, with a focus on developing next-generation therapies. This positions them to benefit from the projected growth in this sector. NVS Novartis is mentioned as a developer of next-generation immune checkpoint inhibitors, including specific pipeline drugs like CFZ533 and LAG525. This indicates active participation and potential growth in the expanding market. JNJ Janssen Pharmaceuticals (part of Johnson & Johnson) is mentioned for its drug DARZALEX in the context of immune checkpoint inhibitors. This indicates a significant player in a growing market with potential for future sales. SNY Sanofi is mentioned for its drug SAR650984 in the context of immune checkpoint inhibitors. This highlights their involvement in a growing market with potential for future revenue from this therapeutic area. EXR EpicentRx is mentioned for its drug RRx-001 in the context of immune checkpoint inhibitors. This indicates their participation in a growing market with potential for future success.

Immune Checkpoint Inhibitors Market Size, Share, Trends, and Global Forecast to 2030 | Next-Generation Targets and Combination Therapies Create New Growth Opportunities Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Immune Checkpoint Inhibitors Market: Industry Trends and Global Forecasts, till 2030" has been added to ResearchAndMarkets.com's offering.

The global immune checkpoint inhibitors market is estimated to be worth USD 62 billion in the current year and is projected to reach USD 246 billion by 2035. The market is expected to grow at a CAGR of 14.7% during the forecast period, supported by expanding cancer indications, increasing clinical research activity, next-generation immune checkpoint targets, and the development of combination treatment strategies.

Cancer remains a major cause of mortality worldwide. In the US alone, approximately 0.6 million cancer-related deaths were recorded in 2019. The World Health Organization has projected a 70% increase in new cancer cases globally over the next 20 years. Although chemotherapy, surgery, and radiation therapy remain established treatment options, their effectiveness can be limited in advanced-stage cancers. Treatment-related toxicity and the non-specific effects of conventional therapies also continue to affect patient quality of life.

Immune checkpoint inhibitors have emerged as an important category of targeted cancer treatment. These therapies have demonstrated the potential to improve outcomes for patients with advanced tumors by targeting immune checkpoint pathways associated with cancer progression. In 2011, Yervoy (ipilimumab), an anti-CTLA-4 monoclonal antibody developed by Bristol-Myers Squibb, became the first immune checkpoint inhibitor approved by the FDA for metastatic melanoma.

Early therapies targeting PD-1, PD-L1, and CTLA-4 established the clinical potential of immune checkpoint modulation. However, treatment resistance among certain patient populations has encouraged researchers and drug developers to investigate additional targets and combination regimens. Emerging inhibitory receptors include LAG-3, TIM-3, TIGIT, VISTA, and B7-H3, while stimulatory receptors under investigation include OX40, ICOS, GITR, 4-1BB, and CD40.

Clinical research involving combinatorial immune checkpoint blockade and co-stimulation is expected to broaden therapeutic applications and improve treatment outcomes. These molecules are also being evaluated for their potential role in immune tolerance and the treatment or prevention of autoimmune diseases. Encouraging clinical results and the progression of pipeline therapies through late-stage development are expected to support sustained immune checkpoint inhibitors market growth.

Market Segmentation

The report evaluates the immune checkpoint inhibitors market across major commercial, clinical, and geographic segments:

Clinical Research and Market Insights

Since 2000, more than 3,600 clinical trials evaluating PD-1 / PD-L1 targeting immune checkpoint inhibitors have been registered worldwide. More than 450 scientific articles report findings from completed and ongoing studies, with many published in peer-reviewed journals with impact factors ranging from 1 to 20. The report also presents key findings from more than 85 clinical research publications covering approved and under development PD-1 / PD-L1 targeting drugs.

Current clinical development includes new molecular entities designed to block PD-1 signaling across multiple tumor types, including metastatic cancers. Trials are also investigating approved immune checkpoint inhibitors in combination with other therapeutic classes. PD-L1 expression remains an important consideration in the design of immune checkpoint blockade studies, particularly for patient selection and treatment response assessment.

Trial design continues to influence development efficiency, endpoint selection, patient eligibility, and the evaluation of superiority, non-inferiority, or equivalence. Late phase studies increasingly focus on long term treatment outcomes, safety profiles, and therapy-related toxicities across diverse patient groups. Although several PD-1 / PD-L1 targeting therapies are already commercially available, additional biological candidates are progressing through clinical evaluation and may enter the market in the coming years.

Competitive Landscape and Research Coverage

Example companies active in the immune checkpoint inhibitors market include:

The report provides market sizing and revenue forecasts across immune checkpoint targets, disease indications, mechanisms of action, therapeutic modalities, therapy types, routes of administration, and geographic regions. It also assesses marketed and pipeline molecules by development phase, target checkpoint, modality, administration route, therapeutic area, and treatment strategy.

Additional analysis includes profiles of next generation immune checkpoint modulator developers, product portfolios, financial information where available, recent developments, and future outlooks. The research examines more than 490 grants awarded to institutes involved in next generation immune checkpoint therapy-related projects, including funding amounts, support periods, research priorities, grant mechanisms, recipient organizations, and prominent targets.

The report further reviews partnerships and collaborations by deal type, year, and region. Target competitiveness analysis considers the number of lead molecules, development stage, grants, and scientific publications associated with individual immune checkpoint targets. Big pharma participation is assessed according to pipeline size, target disease indications, partnership activity, and target portfolios.

Strategic Value for Market Stakeholders

The report addresses the number of companies operating in the market, leading industry participants, major growth drivers and barriers, current and projected market size, expected CAGR, and the distribution of opportunities across key segments. Revenue projections and competitive analysis can support established companies and emerging entrants in refining market positioning, portfolio planning, partnership strategies, and go-to-market decisions.

Purchasers also receive complimentary PPT insights packs, Excel data packs covering analytical modules, up to 15% complimentary content customization, an in-depth walkthrough with the research team, and a complimentary update when the report is more than six months old.

Key Topics Covered:

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview

3.2. Introduction to Cancer Immunotherapy

3.3. Fundamentals of Cancer Immunotherapy

3.4. Immune Checkpoint Modulators

3.5. First Generation Immune Checkpoint Modulators

3.6. Next Generation Immune Checkpoint Modulators

3.6.1. Types of Next Generation Immune Checkpoint Modulators

3.7. Challenges-related to Immune Checkpoint Modulation-based Therapy

3.8. Future Perspectives

4. CURRENT MARKET LANDSCAPE: MARKETED AND DEVELOPMENT PIPELINE

4.1. Chapter Overview

4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline

4.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Pipeline Analysis

4.3.1. Analysis by Phase of Development

4.3.2. Analysis by Target Immune Checkpoint

4.3.3. Analysis by Mechanism of Action

4.3.4. Analysis by Therapeutic Modality

4.3.5. Analysis by Route of Administration

4.3.6. Analysis by Target Disease Indication

4.3.7. Analysis by Therapeutic Area

4.3.8. Analysis by Popular Oncological Indication(s) and Popular Target Immune Checkpoint

4.3.9. Analysis by Popular Non-Oncological Indication(s) and Popular Target Immune Checkpoint

4.3.10. Analysis by Popular Disease Indication(s) and Popular Target Immune Checkpoint in Highest Phase of Development

4.4. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers

4.4.1. Analysis by Year of Establishment

4.4.2. Analysis by Company Size and Geographical Location

4.4.3. Leading Developer Companies: Analysis by Number of Pipeline Therapies

4.4.4. Popular Targets: Distribution by Number of Developers

4.4.5. World Map Representation: Analysis by Geography

5. MARKET LANDSCAPE: THERAPIES TARGETING CD47

5.1. Chapter Overview

5.2. Next Generation Immune Checkpoint Inhibitors: Development Pipeline of CD47 Targeting Therapies

5.3. Next Generation Immune Checkpoint Inhibitors: Pipeline Analysis of CD47 Targeting Therapies

5.3.1. Analysis by Phase of Development

5.3.2. Analysis by Therapeutic Modality

5.3.3. Analysis by Route of Administration

5.3.4. Analysis by Target Disease Indication

5.4. Next Generation Immune Checkpoint Inhibitors: List of Companies Developing CD47 Targeting Therapies

5.4.1. Analysis by Year of Establishment

5.4.2. Analysis by Company Size and Geographical Location

5.4.3. Leading Developers: Analysis by Number of Therapies

5.4.4. World Map Representation: Analysis by Geography

6. MARKET LANDSCAPE: THERAPIES TARGETING 4-1BB

6.1. Chapter Overview

6.2. Next Generation Immune Checkpoint Stimulators: Development Pipeline of 4-1BB Targeting Therapies

6.3. Next Generation Immune Checkpoint Stimulators: Pipeline Analysis of 4-1BB Targeting Therapies

6.3.1. Analysis by Phase of Development

6.3.2. Analysis by Therapeutic Modality

6.3.3. Analysis by Route of Administration

6.3.4. Analysis by Target Disease Indication

6.4. Next Generation Immune Checkpoint Stimulators: List of Companies Developing 4-1BB Targeting Therapies

6.4.1. Analysis by Year of Establishment

6.4.2. Analysis by Company Size and Geographical Location

6.4.3. Leading Developers: Analysis by Number of Therapies

6.4.4. World Map Representation: Analysis by Geography

7. CLINICAL TRIAL ANALYSIS

7.1. Chapter Overview

7.2. Scope and Methodology

7.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Clinical Trial Analysis

7.3.1. Analysis by Trial Registration Year

7.3.2. Analysis by Trial Phase

7.3.3. Analysis by Trial Recruitment Status

7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled

7.3.5. Analysis by Study Design

7.3.6. Analysis by Sponsor / Collaborator

7.3.7. Leading Players: Analysis by Number of Registered Trials

7.3.8. Word Cloud: Key Focus Areas

7.3.9. Analysis by Target Immune Checkpoint

7.3.10. Analysis by Target Therapeutic Area

7.3.11. Popular Indications: Analysis by Number of Registered Trials

7.3.12. Popular Interventions: Analysis by Number of Registered Trials

7.3.13. Geographical Analysis by Number of Registered Trials

7.3.14. Geographical Analysis by Number of Patients Enrolled

8. COMPANY PROFILES: NEXT GENERATION INHIBITORS AND STIMULATORS

8.1. Chapter Overview

8.2. Bristol-Myers Squibb

8.2.1. Company Overview

8.2.2. Financial Information

8.2.3. Next Generation Immune Checkpoint Therapeutics Portfolio

8.2.4. Recent Developments and Future Outlook

8.3. GlaxoSmithKline

8.3.1. Company Overview

8.3.2. Financial Information

8.3.3. Next Generation Immune Checkpoint Therapeutics Portfolio

8.3.4. Recent Developments and Future Outlook

8.4. Incyte

8.4.1. Company Overview

8.4.2. Financial Information

8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio

8.4.4. Recent Developments and Future Outlook

8.5. Novartis

8.5.1. Company Overview

8.5.2. Financial Information

8.5.3. Next Generation Immune Checkpoint Therapeutics Portfolio

8.5.4. Recent Developments and Future Outlook

8.6. Trillium Therapeutics

8.6.1. Company Overview

8.6.2. Financial Information

8.6.3. Next Generation Immune Checkpoint Therapeutics Portfolio

8.6.4. Recent Developments and Future Outlook

9. ACADEMIC GRANTS ANALYSIS

9.1. Chapter Overview

9.2. Scope and Methodology

9.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Analysis of Grants Awarded by the National Institutes of Health (NIH)

9.3.1. Analysis by Year of Grant Award

9.3.2. Analysis by Amount Awarded

9.3.3. Analysis by Administering Institute Center

9.3.4. Analysis by Funding Institute Center

9.3.5. Analysis by Support Period

9.3.6. Analysis by Funding Institute Center and Support Period

9.3.7. Analysis by Type of Grant Application

9.3.8. Analysis by Purpose of Grant Award

9.3.9. Analysis by Grant Mechanism

9.3.10. Word Cloud: Emerging Focus Areas

9.3.11. Popular Target Immune Checkpoints: Analysis by Number of Grants

9.3.12. Analysis of Grant Amount Awarded by Target Immune Checkpoints

9.3.13. Analysis by Study Section Involved

9.3.14. Popular NIH Departments: Analysis by Number of Grants

9.3.15. Analysis by Types of Recipient Organizations

9.3.16. Popular Recipient Organizations: Analysis by Number of Grants

9.3.17. Prominent Program Officers: Analysis by Number of Grants

9.3.18. Regional Analysis of Recipient Organizations

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview

10.2. Partnership Models

10.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Partnerships and Collaborations

10.3.1. Analysis by Year of Partnership

10.3.2. Analysis by Type of Partnership

10.3.3. Analysis by Number of Partnership and Target Immune Checkpoint

10.3.4. Analysis by Year of Partnership and Type of Partner

10.3.5. Analysis by Type of Partnership and Type of Partner

10.3.6. Most Active Players: Analysis by Number of Partnerships

10.4. Regional Analysis

10.4.1. Intercontinental and Intracontinental Agreements

11. TARGET COMPETITIVENESS ANALYSIS

11.1. Chapter Overview

11.2. Scope and Methodology

11.3. Key Parameters

11.4. Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors and Stimulators

11.4.1. Four-Dimensional Bubble Analysis

11.4.2. Five-Dimensional Spider Web Analysis

12. BIG PHARMA INITIATIVES

12.1. Chapter Overview

12.2. Big Pharma Initiatives Focused on Next Generation Immune Checkpoint

12.2.1. Analysis by Number of Initiatives

12.2.2. Analysis by Number of Targets

12.2.3. Analysis by Product Development Strategy

12.2.4. Analysis by Target Immune Checkpoint

12.2.5. Grid Representation: Analysis by Product Development Strategy and Target Immune Checkpoint

12.2.6. Analysis by Type of Intervention

12.3. Analysis by Target Disease Indication(s)

12.3.1. Heat Map: Big Pharma Initiatives Focused on Oncological Indications

12.3.2. Heat Map: Big Pharma Initiatives Focused on Non-Oncological Indications

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

13.1. Chapter Overview

13.2. Forecast Methodology and Key Assumptions

13.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market, Till 2030

13.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Individual Product Sales Forecasts

13.4.1. DARZALEX (Janssen Pharmaceuticals)

13.4.1.1. Target Patient Population

13.4.1.2. Sales Forecast

13.4.2. SAR650984 (Sanofi)

13.4.2.1. Target Patient Population

13.4.2.2. Sales Forecast

13.4.3. RRx-001 (EpicentRx)

13.4.3.1. Target Patient Population

13.4.3.2. Sales Forecast

13.4.4. GSK3359609 (GlaxoSmithKline)

13.4.4.1. Target Patient Population

13.4.4.2. Sales Forecast

13.4.5. Omburtamab (Y-mAbs Therapeutics)

13.4.5.1. Target Patient Population

13.4.5.2. Sales Forecast

13.4.6. APXOO5M (Apogenix)

13.4.6.1. Target Patient Population

13.4.6.2. Sales Forecast

13.4.7. BI 655064 (Boehringer Ingelheim)

13.4.7.1. Target Patient Population

13.4.7.2. Sales Forecast

13.4.8. BMS-986015 (Bristol-Myers Squibb)

13.4.8.1. Target Patient Population

13.4.8.2. Sales Forecast

13.4.9. CFZ533 (Novartis)

13.4.9.1. Target Patient Population

13.4.9.2. Sales Forecast

13.4.10. GBR 830 (Glenmark)

13.4.10.1. Target Patient Population

13.4.10.2. Sales Forecast

13.4.11. KHK4083 (Kyowa Kirin)

13.4.11.1. Target Patient Population

13.4.11.2. Sales Forecast

13.4.12. LAG525 (Novartis)

13.4.12.1. Target Patient Population

13.4.12.2. Sales Forecast

13.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Region

13.5.1. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in US, Till 2030

13.5.2. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in UK, Till 2030

13.5.3. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Germany, Till 2030

13.5.4. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in France, Till 2030

13.5.5. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Italy Till 2030

13.5.6. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Spain, Till 2030

13.5.7. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Australia, Till 2030

13.5.8. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in Japan, Till 2030

13.5.9. Next Generation Immune Checkpoint Inhibitors and Stimulators Market in India, Till 2030

13.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Therapeutic Area

13.6.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Oncological Indications, Till 2030

13.6.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Non-oncological Indications, Till 2030

13.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Disease Indication

13.7.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Atopic Dermatitis, Till 2030

13.7.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Breast Cancer, Till 2030

13.7.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Chronic Lymphocytic Leukemia, Till 2030

13.7.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Colorectal Cancer, Till 2030

13.7.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Head and Neck Cancer, Till 2030

13.7.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lung Cancer, Till 2030

13.7.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Lupus Nephritis, Till 2030

13.7.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Melanoma, Till 2030

13.7.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Multiple Myeloma, Till 2030

13.7.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Neuroblastoma, Till 2030

13.7.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Primary Sjogren's Syndrome, Till 2030

13.7.12. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Ulcerative Colitis, Till 2030

13.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Target Immune Checkpoint

13.8.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for B7-H3 Targeting Therapies, Till 2030

13.8.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD38 Targeting Therapies, Till 2030

13.8.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD40 Targeting Therapies, Till 2030

13.8.4. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for CD47 Targeting Therapies, Till 2030

13.8.5. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for ICOS Targeting Therapies, Till 2030

13.8.6. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for KIR Targeting Therapies, Till 2030

13.8.7. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for LAG-3 Targeting Therapies, Till 2030

13.8.8. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for OX40 Targeting Therapies, Till 2030

13.9. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Mechanism of Action

13.9.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Inhibitory Therapies, Till 2030

13.9.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Stimulatory Therapies, Till 2030

13.10. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapeutic Modality

13.10.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monoclonal Antibody, Till 2030

13.10.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Small Molecules, Till 2030

13.11. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Type of Therapy

13.11.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Monotherapy, Till 2030

13.11.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Combination Therapy, Till 2030

13.11.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Both, Till 2030

13.12. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market: Distribution by Route of Administration

13.12.1. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intracerebroventricular Therapies, Till 2030

13.12.2. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Intravenous Therapies, Till 2030

13.12.3. Global Next Generation Immune Checkpoint Inhibitors and Stimulators Market for Subcutaneous Therapies, Till 2030

14. CONCLUDING REMARKS

14.1. Chapter Overview

14.2. Key Takeaways

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES [139]

LIST OF TABLES [193]

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/izj3td

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.